Editorial
Myeloid Derived Suppressor Cells: Fuel the Fire
| B. R. Achyut* and Ali S. Arbab | |
| Tumor Angiogenesis Lab, Biochemistry and Molecular Biology Department, Cancer Center, Georgia Regents University, USA | |
| *Corresponding Author : | Bhagelu R Achyut, PhD Tumor Angiogenesis Lab, Cancer Center Georgia Regents University, 1410 Laney Walker Blvd CN3144B, Augusta, GA 30912, USA Tel: 706-721-4375 Fax: 706-434-6406 E-mail: bachyut@gru.edu |
| Received July 15, 2014; Accepted July 17, 2014; Published July 24, 2014 | |
| Citation: Achyut BR, Arbab AS (2014) Myeloid Derived Suppressor Cells: Fuel the Fire. Biochem Physiol 3:e123. doi: | |
| Copyright: © 2014 Achyut BR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Low oxygen tension, hypoxia, is a characteristic of many tumors and associated with the poor prognosis. Hypoxia invites bone marrow derived cells (BMDCs) from bone marrow to the site of tumor. These recruited CXCR4+ BMDCs provide favorable environment for the tumor growth by acquiring pro-angiogenic phenotype such as CD45+VEGFR2+ Endothelial Progenitor Cells (EPC), or CD45+Tie2+ myeloid cells. CD11b+ CD13+ myeloid population of the BMDCs modulate tumor progression. These myeloid populations retain immunosuppressive characteristics, for example, myeloid derived suppressor cells (MDSCs), and regulates immune- suppression by inhibiting cytotoxic T cell function. In addition, MDSCs were observed at the premetastatic niche of the distant organs in other tumors. Protumorigenic and prometastatic role of the myeloid cells provides a basis for therapeutic targeting of immunosuppression and thus inhibiting tumor development and metastasis.
